Theriva Biologics Seeks Shareholder Approval for Issuance of 16.2 Million Shares Under Warrant Agreement
I'm PortAI, I can summarize articles.
Theriva Biologics Inc. failed to hold its Special Meeting of Stockholders on December 15, 2025, due to a lack of quorum. The meeting aimed to seek approval for issuing 16.2 million shares under a warrant agreement. The company must call additional meetings every 60 days until approval is obtained or the warrants expire. A new meeting date will be announced, and proxy materials will be distributed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments